ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1839

Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion

J. Patricia Dhar1,2, Lynnette Essenmacher3, Renee Dhar4, Ardella Magee5, Joel Ager6 and Robert Sokol7, 1Internal Medicine, Wayne State University, Detroit, MI, 2Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, 3Wayne State University School of Medicine, Detroit, MI, 4CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, 5Clinical and Translational Research Center, Wayne State University, Detroit, MI, 6Family Medicine, Wayne State University School of Medicine, Detroit, MI, 7Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Human papillomavirus (HPV), immune response, Safety, systemic lupus erythematosus (SLE) and vaccines

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Women with SLE are at
increased risk for HPV-related cervical disease. The qHPV vaccine immunizes and
is protective against HPV types that cause the majority of cervical cancer
(types 16 &18) and genital warts (types 6 &11).This study evaluated the
safety and immunogenicity of qHPV vaccine in SLE.

Methods:

In this
trial, 34 women ages 19-50 years
(yrs.) with a history of mild to moderate SLE by ACR criteria & minimally
active or inactive SLE received qHPV vaccine at the standard dosing schedule
(0, 2 months, 6 months). This study was approved by the Human Investigation
Committee at Wayne State University & the U.S. Food and Drug
Administration. Patients were excluded if they had active disease
(SELENA-SLEDAI >2), history of severe disease, deep venous thrombosis, on
>400 mg/day of hydroxychloroquine, on >15 mg/day of prednisone, or
had active infections.  Patients were monitored for adverse events (AE), SLE
flare, generation of thrombogenic antibodies and thrombosis.  Antibody (Ab) levels
to HPV 6,11,16 &18 were evaluated pre-vaccine administration and one month
after the 3rd vaccine shot. Ab levels were measured by HPV
competitive Luminex Immunoassay.
Analysis of rise in Geometric Mean
Titers (GMTs) was performed using paired t-tests and of seropositivity status
(y/n) using McNemar’s test. 

 

Results:

The women
in the study: African-American (79%), mean age 38.1 yrs., mean age at diagnosis
of SLE at 28.6 yrs., 32.4% had a history of smoking, 91% had 4 or more sexual
partners, 50% had a history of sexually transmitted diseases, and only 27.3%
used condoms on a regular basis. History of abnormal pap smears occurred
in 52.9% {range: ASCUS (atypical glandular cells of undetermined significance)
to CIN 3 (cervical intraepithelial neoplasia grade 3)}. Vaccine site reactions
(VSRs) occurred in 59%, all mild, most common reaction being pain (VSRs in
normal women=83.9% for Gardasil® vs. 75.4% for controls). For the non-vaccine
site AEs (nvAE), 97% experienced at least one nvAE;
there were 487 nvAEs reported from 33 patients and 90% of these were mild.
There were 9 serious AEs, none related to vaccine or SLE and all resolved. The
most common nvAEs reported were musculoskeletal (n=106) followed by nervous
system (n=98, mostly headaches), gastrointestinal (n=49), general disorders
(n=45) and dermatologic (n=45). None of the nvAEs were related to vaccine or
SLE. No patient experienced any flare of SLE, thrombosis, or generation of
thrombogenic antibodies.

Positive HPV
Ab titers were seen in 21-53% of the women at baseline for all HPV types (52.9%
for HPV 6, 20.6% for HPV 11, 44.1% for HPV 16 & 20.6% for HPV 18), indicating
previous exposure to the HPV types in the vaccine. Highly immunogenic responses
were seen in all patients. There was a statistically significant rise in mean (GMTs)
post vaccine series completion for both HPV naive and HPV exposed women for all 4 HPV
types, with a
seroconversion rate of 100% in HPV naïve women. 

Conclusion:

Preliminary
data from our study shows that qHPV vaccine is generally safe, well tolerated,
and highly immunogenic in women with SLE. These results suggest that the
qHPV vaccine may be of benefit in women with SLE who are at increased risk for
HPV-related cervical disease.

 


Disclosure: J. P. Dhar, None; L. Essenmacher, None; R. Dhar, None; A. Magee, None; J. Ager, None; R. Sokol, None.

To cite this abstract in AMA style:

Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol R. Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/safety-and-immunogenicity-of-quadrivalent-human-papilloma-virus-qhpv-vaccine-gardasil-in-systemic-lupus-erythematous-sle-phase-i-trial-completion/. Accessed March 8, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-immunogenicity-of-quadrivalent-human-papilloma-virus-qhpv-vaccine-gardasil-in-systemic-lupus-erythematous-sle-phase-i-trial-completion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.